What the business is, and whether it's a good one at a fair price.
Manufactures active pharmaceutical ingredients (APIs), also known as bulk drugs, which are the chemical compounds used by other drug makers to produce finished medicines. The product slate is expanding into regulated-market molecules, with new additions cited as Vonoprazon Fumarate, Pretomanid, and Edoxaban Tosylate. Revenue comes from two streams: domestic sales (around 54% of revenue) and exports (around 46%), with Africa (33% of exports), Asia (35%), and Europe (24%) as the named export geographies. The manufacturing base produced 1,733 metric tonnes in FY26 (up about 25% year-on-year), running against installed capacity of 2,400 MTPA, and the facilities cleared USFDA and EU GMP inspections with zero 483 observations. Costs are dominated by raw materials at 66.1% of revenue, with employee cost at 3.4% and other operating expenses at 10.9%. Depreciation is 1.5% and capex 1.0% of revenue, indicating a relatively capital-light profile. EBITDA margin compressed to 8.56% in FY26, with net profit of Rs. 41.05 crore on revenue of Rs. 771.66 crore.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from ANUH PHARMA LIMITED's filed financials and exchange disclosures
ANUH PHARMA LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol ANUHPHR.
Yes. Over the trailing twelve months ANUH PHARMA LIMITED reported a net profit of ₹52 Cr on revenue of ₹965 Cr.
Yes. The dividend yield is 1.57% at the current price. It paid out 37% of its profit as dividend in FY26.
Effectively yes. It holds ₹8 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, ANUH PHARMA LIMITED ranks 52 of 169 in Pharmaceuticals — cheaper than 70% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session ANUH PHARMA LIMITED moves 1.08% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by ANUH PHARMA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
